Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor

Live updates

1. 1h ago

   Endeavor Wins Phase 2b for IPF Drug Taladegib

   Endeavor BioMedicines announced that its Phase 2b WHISTLE-PF trial of taladegib met its primary and key secondary endpoints in patients with idiopathic pulmonary fibrosis. The investigational Hedgehog signaling pathway inhibitor demonstrated a statistically significant improvement in lung function compared to placebo, measured by percent predicted forced vital capacity through Week 24. Trial results also showed reduced lung fibrosis and increased total lung capacity on quantitative high-resolution computed tomography imaging. Patients receiving the drug experienced symptomatic improvement from baseline. Endeavor plans to advance the IPF hopeful into Phase III trials following the mid-stage victory.

   Why it matters

   Current standard-of-care treatments for idiopathic pulmonary fibrosis only slow the decline of lung function, creating high demand for disease-reversing therapies. Endeavor is positioning its Hedgehog inhibitor to challenge existing market incumbents. The positive mid-stage data bolster the company's development timeline as it prepares for late-stage clinical evaluation.

   What is confirmed

   • Endeavor BioMedicines reported that its Phase 2b WHISTLE-PF trial of taladegib met its primary and key secondary endpoints in patients with idiopathic pulmonary fibrosis.
   • The trial demonstrated a statistically significant improvement in percent predicted forced vital capacity compared to placebo.
   • Patients treated with taladegib showed reduced lung fibrosis and increased total lung capacity on quantitative high-resolution computed tomography imaging.
   • Endeavor plans to move the investigational drug into Phase III clinical development.

   Still unconfirmed

   • Endeavor stated that the IPF drug can reverse the disease.

   What to watch next

   • Presentation of detailed trial data at a future medical meeting
   • Initiation of the Phase III clinical trial for taladegib
   Sources used for this update (9)

   1. Fierce Biotech — Endeavor’s threat to IPF incumbents increases after phase 2 win for Hedgehog inhibitor
   2. Endpoints News — Endeavor notches major mid-stage trial win, says IPF drug can reverse disease
   3. Business Wire — Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib Meets Primary and Key Secondary Endpoints in Patients With IPF
   4. FirstWord Pharma — Endeavor to move IPF hopeful into Phase III after mid-stage victory
   5. Clinical Trials Arena — Endeavor’s Phase IIb IPF study of taladegib meets endpoints
   6. theclinicaltimes.com — Endeavor reports phase 2b success for potential IPF drug
   7. www.biospace.com — Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial ... - BioSpace
   8. endeavorbiomedicines.com — Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib ...
   9. finance.yahoo.com — Endeavor BioMedicines' WHISTLE-PF Phase 2b Trial of Taladegib ...
   confidence 100%